Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Prediction: This Is What Eli Lilly Stock Will Do Next (Hint: It's Not a Stock Split)
With a market capitalization of over $800 billion, Eli Lilly (NYSE: LLY) is the largest pharmaceutical company in the world. Much that is thanks to the rise of glucagon-like peptide-1 (GLP-1) agonists such as Mounjaro and Zepbound, which are fueling a new wave of growth for the company.
Prediction: This Will be Eli Lilly's Next Big Move.
Eli Lilly’s stock has climbed almost 60% this year and trades for more than $900. The pharma giant also has seen soaring sales thanks to its dominance in the high-growth weight loss drug market. This is thanks to Lilly's dominance in the billion-dollar weight loss drug market.
Eli Lilly & Co. stock underperforms Monday when compared to competitors
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with unparalleled accuracy. Back To Top
Prediction: This Will be Eli Lilly's Next Big Move.
Eli
Lilly
(NYSE: LLY) offers investors the same thing as many other big pharma companies: a certain level of security when it comes to revenue. Since people need their medicines regardless of the ...
Little Support For Eli Lilly's High Valuation
An analysis of Eli Lilly's stock reveals high premium, overvaluation concerns and a low dividend yield. LLY is rated hold due to expensive valuation. See more.
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 589.81% and currently trading at $912.00. The company has been around since 1876 and the stock didn’t go public until 1952 but in the last 4 years,
1d
Eli Lilly Is Finally Cheap, Warranting An Upgrade To Buy
Eli Lilly's long-term growth prospects are strong with improved supply, new growth opportunities, and competitive positioning ...
3d
Eli Lilly urges court to toss $183 mln Medicaid fraud judgment
Drugmaker Eli Lilly on Wednesday urged a federal appeals court to overturn a $183 million judgment against it in a case ...
USA Today
6d
New eczema drug from Eli Lilly receives FDA approval for children and adults
On Friday, the U.S. Food and Drug Administration approved
Eli
Lilly
's eczema drug for use in adults and children 12 and ...
1d
Eli Lilly: Sticking With A $1000 Target Ahead Of Q3 Earnings, New Trading Range
Eli Lilly surged 58% in 2024, driven by weight-loss drugs and strong earnings. The technical chart shows consolidation. See ...
1d
Why Novo Nordisk Stock Fell While Eli Lilly and Viking Therapeutics Bumped Higher Today
The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.
12d
Eli Lilly’s new CFO is a 23-year company veteran—showing how pharma firms rely on a ‘deep bench of qualified talent’
Good morning. Eli Lilly and Company has promoted longtime executive Lucas Montarce to the role of CFO. The move is similar to ...
Ibj.com
4d
Eli Lilly requests records of people who took copies of its weight-loss drug
The letter is the latest sign that the battle between the brand-name drug manufacturers and the companies that make and sell ...
Investor's Business Daily on MSN
1d
Netflix, Eli Lilly Lead 5 Fast Growers Near Buy Points
Netflix and Eli Lilly lead this weekend's list of five stocks near buy points that are all enjoying rapid sales growth.
2d
Eli Lilly: I Admit Defeat As I Understated Its Growth Prospects (Upgrade)
Eli Lilly's valuation is a critical concern, but its robust execution has improved its ability to actualize its high-growth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
United States
S&P 500 Index
New York Stock Exchange
Novo Nordisk
Trade
Feedback